Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vitamin B3 supplement could boost energy in kidney disease

NCT ID NCT07693543

Disease control Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This study tests whether a dietary supplement called nicotinamide riboside (a form of vitamin B3) can be safely taken by adults with moderate chronic kidney disease. The main goal is to see if it's feasible for participants to take the supplement daily and complete study procedures. The study also explores whether NR affects markers of cellular energy, blood vessel function, and physical function. Participants will take NR and a placebo in random order, each for 12 weeks, without knowing which they are taking.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nicotinamide riboside (a form of vitamin B3)
What this could lead to
If successful, this could point toward a dietary supplement that supports energy metabolism and kidney health in people with chronic kidney disease.
What could go wrong
This is a small, early-phase pilot study focused on feasibility, not proof of effectiveness. The supplement may not improve kidney function or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Moderate chronic kidney disease not treated with dialysis, defined as eGFR 30-59 mL/min/1.73 m2 using the CKD-EPI equation. * Urine albumin-to-creatinine ratio (uACR) \<300 mg/g. * Able to provide informed consent. * Able to walk unassisted from room to room, with usual assistive device allowed if approved by study safety assessment. * Willing and able to comply with study procedures, visits, and study product administration. Exclusion Criteria: * Pregnancy. * Expectation to start dialysis within 6 months. * Unable to walk unassisted from room to room. * Institutionalization or inability to consent. * End-stage liver disease with cirrhosis. * HIV. * Oxygen-dependent COPD. * Baseline systolic blood pressure \>170 mmHg or diastolic blood pressure \>100 mmHg. * Current participation in another interventional trial. * Use of immunosuppressive medications, including steroids or calcineurin inhibitors. * Malignancy requiring active treatment or currently under surveillance at the discretion of the investigator. * Hospitalization for myocardial infarction, unstable angina, cerebrovascular accident, or unstable cardiac chest pain within the prior 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Altman Clinical and Translation Research Institute

    San Diego, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.